january #fda approvals include abbvie’s #skyrizi treat psoriatic arthritis #kimmtrak, first-in-class t-cell receptor tcr immunotherapy. pfizer’s oral jak1 inhibitor #cibinqo was ok’d moderate-to-severe eczema, plus other approvals.